Other languages Q32 Bio Inc.

Equities

QTTB

US7469641051

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
25.59 ^USD	-0.70%		-9.38%	+135.47%

11/04	Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	MT
03/04	Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Q32 Bio Inc. completed the acquisition of Homology Medicines, Inc. from 5AM Venture Management, LLC, Arch Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P. managed by Arch Venture Partners, L.P., Pfizer Inc. and TLS Beta Pte. Ltd. in a reverse merger transaction.	25/03
Homology Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Neurogene Names Julie Jordan as Chief Medical Officer	17/01
Homology Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Homology Medicines, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Homology Medicines, Inc. Approves Reduction in Workforce	28/23/28
Homology Medicines, Inc. Approves Reduction in Workforce	28/23/28
Homology Medicines Announces Plan to Evaluate Strategic Options	27/23/27
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting	16/23/16
Homology Medicines, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
Bb Biotech : livello investimento 1* trim al 114%, dividendo di 2,85 franchi	21/23/21
Homology Medicines Files for $250 Million Mixed Shelf	10/23/10
Homology Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	10/23/10
Homology Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10
Homology Medicines, Inc. Announces Promotion of Julie Jordan to Chief Medical Officer	09/23/09
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy	23/23/23
Homology Medicines Doses First Participant in HMI-103 Gene Editing Trial; Expects Initial Data From HMI-103, HMI-203 Trials in 2023	05/23/05
Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials	05/23/05
Top Premarket Decliners	28/22/28
Homology Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Q32 Bio Inc.

Equities

QTTB

US7469641051

Other languages

Filters